FABP4 and hepatocellular carcinoma: On the other hand, the serum FABP4 levels have been found increased in patients with hepatocellular carcinoma, thereby suggesting a pivotal role as a potential biomarker not only for MAFLD, but also for end-stage liver disease [112].